ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Allarity Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.87−0.02 (-2.46%)
Close on Oct 19, 2026
- Market cap
- $13.89M
- P/E (TTM)
- –
- Dividend yield
- –
Allarity Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Market Cap | $13.89M | $164.85M |
| Enterprise Value | $17.77M | $87.06M |
| PB Ratio | 3.93 | 2.03 |
| P/TBV Ratio | 3.93 | 2.31 |
Income (trailing twelve months)
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$10.80M | -$21.44M |
| Net Income | -$12.33M | -$22.46M |
| EBITDA | -$10.80M | -$16.91M |
| EPS (Diluted) | -$0.78 | -$0.83 |
Returns
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -157.1% | -53.1% |
| Return on Assets (ROA) | -46.3% | -41.0% |
| Return on Invested Capital (ROIC) | -956.6% | -32.0% |
| Return on Capital Employed (ROCE) | -305.3% | -37.8% |
Balance sheet
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $16.98M | $62.42M |
| Total Debt | $20.86M | $120.13M |
| Net Cash (Debt) | -$3.88M | $15.68M |
| Net Cash Per Share | -$0.24 | $0.66 |
| Equity (Book Value) | $3.54M | $48.79M |
| Book Value Per Share | $0.22 | $1.36 |
| Tangible Book Value | $3.54M | $23.06M |
| Working Capital | $3.15M | $75.77M |
Financial position
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.11 | 3.30 |
| Quick Ratio | 0.59 | 2.39 |
| Debt / Equity | 5.90 | 0.51 |
| Interest Coverage | -10.15 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$13.71M | -$12.35M |
Efficiency
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.54M | -$703.34K |
| Employee Count | 8 | 74 |
Dividends and yields
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -88.8% | -22.7% |
| Buyback Yield | 6.39% | -0.73% |
| Shareholder Yield | 6.39% | 0.00% |
Shares
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 15,910,700 | 58,179,650 |
| Shares Change (QoQ) | 0.58% | 0.54% |
| Float | 14,602,300 | 49,173,100 |
| Shares Held by Insiders | 8.22% | 11.6% |
| Shares Held by Institutions | 8.05% | 59.4% |
Scores
| Measure | Allarity Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -6.64 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Allarity Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.